Listen to Gynecologic Oncology

Editor's Choice: Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201 Editorial: MEK-Ing progress in low-grade serous ovarian cancer Hosted by: Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, United States of America Featuring: Rachel N. Grisham MD, Memorial Sloan Kettering Cancer Center, New York, United States of America David M. Gers...

Editor's Choice: Pregnancies in gynecologic oncologists: An assessment of pregnancy policies and complications within a surgical subspecialty Editorial: Pregnancy complications in gynecologic oncologists – A call to action to do better Hosted by: Paola Gehrig, MD University of Virginia , Charlottesville, United States of America Featuring: Kelsey Goon, MD University of Chicago, United States of America Kathryn A. Mills, MD University of Chicago, United States of Ame...

Editor's Choice: FIGO 2023 staging may result in overtreatment of early-stage endometrial cancer Editorial: A path to precision in endometrial cancer management: Moving past FIGO 2023 Hosted by: David Gaffney, MD, PhD The University of Utah, Salt Lake City, Utah, United States of America Featuring: Allison Roy, MD SUNY Upstate Medical University, Syracuse, NY, United States of America Jessica N. McAlpine University of British Columbia, Vancouver, BC, Canada David Mu...

Editor's Choice: Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 update Editorial: The evolving landscape of personalized perioperative care: A commentary on the 2026 ERAS® Gynecologic oncology guidelines Hosted by: Sean C. Dowdy, MD; Division of Gynecologic Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA Featuring: Gregg Nelson, MD, PhD; Department of Obstetrics & Gynecology, Cumming School of Medicine, Universi...

Editor's Choice: Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial Editorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancer Hosted by: Amanda Nickles Fader, MD; Johns Hopkins Medicine Baltimore, MD, USA Featuring: Kathleen Moore, M...